Preclusion of Ischemic Stroke Patients from Intravenous Tissue Plasminogen Activator Treatment for Mild Symptoms Should Not be Based on Low National Institutes of Health Stroke Scale Scores
Preclusion of Ischemic Stroke Patients from Intravenous Tissue Plasminogen Activator Treatment for Mild Symptoms Should Not be Based on Low National Institutes of Health Stroke Scale Scores
复制标题
DOI：
10.1016/j.jstrokecerebrovasdis.2013.01.021
复制
发表时间：
2013-05-01
影响因子：
2.5
通讯作者：
Nolte, Christian H.
中科院分区：
文献类型：
--
作者：
Wendt, Matthias;Tuetuencue, Serdar;Nolte, Christian H.
背景：静脉注射组织纤溶酶原激活剂（IV tPA）可改善中风后的神经系统结果，但不推荐用于通常按美国国立卫生研究院中风量表（NIHSS）下限分类的轻微神经功能缺损的患者。由于 NIHSS 并未捕获所有中风体征，因此使用严格的截止值可能会将功能受损的中风患者排除在 IV tPA 治疗之外。方法：我们描述了来自我们医院溶栓数据库的患者的功能损伤、安全性和临床结果，这些患者尽管有轻微的神经功能缺损，但仍患有被认为致残的中风。我们使用了 2 个截止值：NIHSS 分数
Background: Intravenous tissue plasminogen activator (IV tPA) improves neurologic outcome after stroke, but is not recommended for patients with minor neurologic deficits commonly classified by a lower cutoff on the National Institutes of Health Stroke Scale (NIHSS). Because not all stroke signs are captured on the NIHSS, the use of a strict cutoff may exclude functionally impaired stroke patients from IV tPA treatment. Methods: We described functional impairment, safety, and clinical outcome in patients derived from our hospital thrombolysis database who had stroke that was considered disabling despite a neurologic deficit that was considered mild. We used 2 cutoffs: NIHSS score